Sylvester Comprehensive Cancer Center

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    		Coordinator:
    RCemailImg Dina Caceres
    RCphone +1 (305) 2437561

    IRB: 20170529

    		SDG: Breast Cancer
    Disease Site(s):

    Breast,Colon,Kaposis sarcoma,Kidney,Larynx,Liver,Lymphoid Leukemia,Multiple,Multiple Myeloma,Non-Hodgkin Lymphoma,Pancreas,Prostate,Soft Tissue
    Sponsor: ASCO

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • 20200056 - D'Amato Gina

  • Investigator:
    Gina D'Amato
    RCname Email

    		Coordinator:

    IRB: 20200056

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Anus,Bladder,Bones and Joints,Breast,Cervix Uteri,Colon,Esophagus,Kidney,Lip, Oral Cavity and Pharynx,Liver,Lung,Melanoma, skin,Other Digestive Organ,Other Urinary,Ovary,Prostate,Rectum,Small Intestine,Soft Tissue,Stomach,Thyroid
    Sponsor: DECIPHERA

    Enrolling Sites:

    Sylvester
    Title:

    A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor
    Eligibility Criteria - NCT03069469 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210890 - Merchan Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    		Coordinator:

    IRB: 20210890

    		SDG: Colorectal Cancer
    Disease Site(s):

    Multiple
    Sponsor: Exelixis Pharmaceuticals

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester
    Title:

    A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
    Eligibility Criteria - NCT03845166 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220871 - MINOCHA VINAY

  • Investigator:
    VINAY MINOCHA
    RCname Email

    		Coordinator:

    IRB: 20220871

    		SDG: Colorectal Cancer
    Disease Site(s):

    Colon
    Sponsor: PFIZER

    Enrolling Sites:

    Plantation
    Sylvester
    Title:

    A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI-H/DMMR METASTATIC COLORECTAL CANCER
    Eligibility Criteria - NCT05217446 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210855 - Pimentel Agustin

  • Investigator:
    Agustin Pimentel
    RCname Email

    		Coordinator:
    RCemailImg Siudy Vasquez Escobar
    RCphone +1 (305) 2432122 x62122

    IRB: 20210855

    		SDG: Colorectal Cancer
    Disease Site(s):

    Multiple
    Sponsor: PFIZER

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC
    Eligibility Criteria - NCT04607421 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220773 - Pimentel Agustin

  • Investigator:
    Agustin Pimentel
    RCname Email

    		Coordinator:

    IRB: 20220773

    		SDG: Colorectal Cancer
    Disease Site(s):

    Colon,Rectum
    Sponsor: Bexion Pharmaceuticals

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1b/2 Placebo Controlled, Double Blinded Study on the Efficacy and Safety of BXQ-350 in Combination with mFOLFOX7 and Bevacizumab in Newly Diagnosed Metastatic Colorectal Carcinoma
    Eligibility Criteria - NCT05322590 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220823 - Pimentel Agustin

  • Investigator:
    Agustin Pimentel
    RCname Email

    		Coordinator:

    IRB: 20220823

    		SDG: Colorectal Cancer
    Disease Site(s):

    Multiple
    Sponsor: Gritstone Bio, Inc.

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester
    Title:

    A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination with Immune Checkpoint Blockade for Patients with Metastatic Colorectal Cancer
    Eligibility Criteria - NCT05141721 *This information has been extracted from " www.clinicaltrials.gov"

  • DECREASE - Portelance, Lorraine

  • Investigator:
    Lorraine Portelance
    RCname Email

    		Coordinator:

    IRB: 20191276

    		SDG: Colorectal Cancer
    Disease Site(s):

    Anus
    Sponsor: ECOG

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Plantation
    Sylvester
    Title:

    A Randomized Phase II Study De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
    Eligibility Criteria - NCT04166318 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210172 - Portelance Lorraine

  • Investigator:
    Lorraine Portelance
    RCname Email

    		Coordinator:
    RCemailImg Samantha St. Armand
    RCphone +1 (305) 2432006

    IRB: 20210172

    		SDG: Colorectal Cancer
    Disease Site(s):

    Rectum
    Sponsor: SCCC

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    Selective Treatment with Magnetic Resonance Image Guided Pelvic Adaptive Radiation Therapy Combined with Total Neoadjuvant ChemoTherapy for the Conservative Management of Locally Advanced Rectal Cancer
    Eligibility Criteria - NCT05412082 *This information has been extracted from " www.clinicaltrials.gov"

  • AMC-095 - Ramos, Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    		Coordinator:

    IRB: 20160656

    		SDG: Lymphoma
    Disease Site(s):

    Anus,Lip, Oral Cavity and Pharynx,Lung,Other Hematopoietic
    Sponsor: AMC

    Enrolling Sites:

    Sylvester
    Title:

    A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors
    Eligibility Criteria - NCT02408861 *This information has been extracted from " www.clinicaltrials.gov"

  • RPL-001-16 - Rodriguez, Estelamari

  • Investigator:
    Estelamari Rodriguez
    RCname Email

    		Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone +1 (786) 5828551

    IRB: 20180802

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Bladder,Breast-Female,Colon,Melanoma, skin,Other Skin
    Sponsor: REPLIMUNE

    Enrolling Sites:

    Sylvester
    Title:

    RPL-001-16: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
    Eligibility Criteria - NCT03767348 *This information has been extracted from " www.clinicaltrials.gov"

  • ATRC-101-A01 - Valdes, Frances

  • Investigator:
    Frances Valdes
    RCname Email

    		Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone +1 (786) 5828551

    IRB: 20200938

    		SDG: Breast Cancer
    Disease Site(s):

    Breast,Colon,Lung,Melanoma, skin,Ovary
    Sponsor: Atreca Inc

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1b Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination with Other Anticancer Agents in Adults with Advanced Solid Malignancies
    Eligibility Criteria - NCT04244552 *This information has been extracted from " www.clinicaltrials.gov"